drugset / Trial / NCT00160615
Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs
Timeline
- Start
- 2001-09-12
- Primary completion
- 2007-01-17
- Completion
- 2007-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levetiracetam | Other / unclassified | 1000 mg | Oral |
| Subject | Levetiracetam | Other / unclassified | 3000 mg | Oral |